Latest news with #Telliez
Business Insider
25-05-2025
- Business
- Business Insider
Innate Pharma SA (IPHYF) Receives a Hold from Kepler Capital
In a report released on May 23, Justine Telliez from Kepler Capital maintained a Hold rating on Innate Pharma SA (IPHYF – Research Report), with a price target of €3.10. The company's shares closed last Friday at $1.45. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter According to TipRanks, Telliez is an analyst with an average return of -8.3% and a 37.36% success rate. Telliez covers the Healthcare sector, focusing on stocks such as Genfit, Adocia SA, and Innate Pharma SA. The word on The Street in general, suggests a Hold analyst consensus rating for Innate Pharma SA with a $3.52 average price target.
Business Insider
26-04-2025
- Business
- Business Insider
Kepler Capital Reaffirms Their Hold Rating on Ipsen (0MH6)
Kepler Capital analyst Justine Telliez maintained a Hold rating on Ipsen (0MH6 – Research Report) on April 24 and set a price target of €120.00. The company's shares closed last Thursday at €98.35. Stay Ahead of the Market: Discover outperforming stocks and invest smarter with Top Smart Score Stocks. Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener. Telliez covers the Healthcare sector, focusing on stocks such as Genfit, Adocia SA, and Innate Pharma SA. According to TipRanks, Telliez has an average return of -9.6% and a 38.20% success rate on recommended stocks. In addition to Kepler Capital , Ipsen also received a Hold from Barclays's Charles Pitman CFA in a report issued on April 22. However, on the same day, Morgan Stanley maintained a Sell rating on Ipsen (LSE: 0MH6). Based on Ipsen's latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of €1.82 billion and a net profit of €113.9 million. In comparison, last year the company earned a revenue of €1.59 billion and had a net profit of €449.2 million
